Vancomycin chemical structure
Find information on thousands of medical conditions and prescription drugs.

Vancomycin

Vancomycin is an antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly Nocardia orientalis). more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

It is often reserved as the "drug of last resort", used only after treatment with other antibiotics had failed. With the increasing prevalence of antibiotic resistant-bacteria, vancomycin has increasingly become a first line therapy when faced with Staphylococcus aureus infections in a patient where antibiotic resistance can reasonably be anticipated.

Vancomycin hydrochloride has been developed by Eli Lilly under the trade name Vancocin®. The patent expired in the early 1980s and generic versions of the drug are now available internationally under various trade names.

In 2004, Eli Lilly licensed Vancocin to ViroPharma Incorporated.

Mechanism of action

Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive bacteria. The mechanism inhibited, and various factors related to entering the outer membrane of Gram-negative organisms mean that vancomycin is not active against Gram-negative bacteria.

Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls.

The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix.

Vancomycin has two chemically distinct rotamers owing to the rotational restriction of the chlorotyrosine residue (on the right hand side of the figure). The form present in the drug is the thermodynamically more stable conformer, and, importantly, has more potent activity. Vancomycin also displays atropisomerism.

Therapeutic considerations

Toxicity

Vancomycin has traditionally been considered a nephrotoxic and ototoxic drug, based on observations by early investigators of elevated serum levels in renally impaired patients who had experienced ototoxicity, and subsequently through case reports in the medical literature. However, as the use of vancomycin increased with the spread of MRSA beginning in the seventies, it was recognized that the previously reported rates of toxicity were not being observed. This was attributed to the removal of the impurities present in the earlier formulation of the drug, although those impurities were not specifically tested for toxicity.

Nephrotoxicity

Subsequent reviews of accumulated case reports of vancomycin-related nephrotoxicity found that many of the patients had also received other known nephrotoxins, particularly aminoglycosides. Most of the rest had other confounding factors, or insufficient data regarding the possibility of such, that prohibited the clear association of vancomycin with the observed renal dysfunction. In 1994, in the largest systematic review to date, Cantu et al found that the use of vancomycin monotherapy was clearly documented in only three of 82 available cases in the literature. Prospective and retrospective studies attempting to evaluate the incidence of vancomycin-related nephrotoxicity have largely been methodologically flawed and have produced variable results. The most methodologically sound investigations indicate that the actual incidence of vancomycin-induced nephrotoxicity is around 5% to 7%. To put this into context, similar rates of renal dysfunction have been reported for cefamandole and penicillin, two reputedly non-nephrotoxic antibiotics. Additionally, evidence to relate nephrotoxicity to vancomycin serum levels is inconsistent. Some studies have indicated an increased rate of nephrotoxicity when trough levels exceed 10 mcg/ml, but others have not reproduced these results. Nephrotoxicity has also been observed with concentrations within the ‘therapeutic” range as well. Essentially, the reputation of vancomycin as a nephrotoxin is over-stated, and it has not been demonstrated that maintaining vancomycin serum levels within certain ranges will prevent its nephrotoxic effects, when they do occur.

Read more at Wikipedia.org


[List your site here Free!]


Clinical characteristics and risk factors of mortality among severe burn patients with isolates of vancomycin-resistant enterococci
From CHEST, 10/1/05 by Heung J. Woo

PURPOSE: Vancomycin-resistant enterococci (VRE) are multi-drug resistant organisms that have emerged as important nosocomial pathogens in recent years. VRE emergence has been blamed mainly on the increased and inappropriate use of antibiotics, in particular, the cephalosporins and the glycopeptide, vancomycin. Burn patients are highly vulnerable to acquiring VRE infection. This study was focused on the clinical characteristics and risk factors of mortality among severe burn patients with VRE isolation during recent 4 years.

METHODS: 104 cases (M:F=69:35) that had VRE isolation from January 1, 2000 to December, 2003, were reviewed. We analyzed clinical characteristics and the risk factors that contribute to death by using univariate and multivariate analyses, retrospectively.

RESULTS: Mean percent total body surface area (%TBSA) of survivors (n=80) and non-survivors (n=24) were 41.64 [+ or -] 20.68% and 58.08 [+ or -] 22.64% (p=0.003). Total 144 strains of VRE were isolated from 104 patients. Most of VRE colonization or infection were caused by Enterococcus faecium (82.6%) and E. casseliflavus (14.6%). There were no significant difference in VRE species distribution between survivors and non-survivors (p> 0.05). The risk factors for mortality were %TBSA burn, APACHE II scores, mechanical ventilation, nasogastric tube, previous use of cefepime and ticarcillin/clavulanate, rectal VRE colonization and initial VRE bacteremia in univariate analysis. However, independent risk factor of death were APACHE II score, mechanical ventilation and initial VRE bacteremia in multivariate analyses.

CONCLUSION: Severe burn patients with VRE isolation should be reassessed carefully, especially in those who had high APACHE II scores at ICU admission, mechanical ventilation and initial VRE bacteremia.

CLINICAL IMPLICATIONS: More strict infection control and efforts to eradicate VRE may be needed among severe burn patients with VRE isolation.

DISCLOSURE: Heung Woo, None.

Heung J. Woo MD * Cheol H. Kim MD Jin K. Kim MD Young I. Park MD In G. Hyun MD Young M. Ahn MD Department of Internal Medicine, Hallym University College of Medicine, Seoul, South Korea

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group

Return to Vancomycin
Home Contact Resources Exchange Links ebay